Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection

Ashish H. Shah, Anil Mahavadi, Long Di, Alexander Sanjurjo, Daniel G. Eichberg, Veronica Borowy, Javier Figueroa, Evan Luther, Macarena Ines de la Fuente, Alexa Semonche, Michael E. Ivan, Ricardo J. Komotar

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Purpose: Extent of resection remains a paramount prognostic factor for long-term outcomes for glioblastoma. As such, supramaximal resection or anatomic lobectomy have been offered for non-eloquent glioblastoma in an attempt to improve overall survival. Here, we conduct a propensity-matched analysis of patients with non-eloquent glioblastoma who underwent either lobectomy or gross total resection of lesion to investigate the efficacy of supramaximal resection of glioblastoma. Methods: Patients who underwent initial surgery for gross total resection or lobectomy for non-eloquent glioblastoma at our tertiary care referral center from 2010 to 2019 were included for this propensity-matched survival analysis. Propensity scores were generated with the following covariates: age, location, preoperative KPS, product of perpendicular maximal tumor diameters, and product of perpendicular FLAIR signal diameters. Inverse probability of treatment weighting (IPTW) with generated propensity scores was used to compare progression-free survival and overall survival. Results: Sixty-nine patients were identified who underwent initial resection of glioblastoma for non-eloquent glioblastoma from 2010 to 2019 (GTR = 37, lobectomy = 32). Using IPTW, overall survival (30.7 vs. 14.1 months) and progression-free survival (17.2 vs. 8.1 months were significantly higher in the lobectomy cohort compared to the GTR group (p < 0.001). There was no significant difference in pre-op or post-op KPS or complication rates between the two groups. Conclusion: Our propensity-matched study suggests that lobectomy for non-eloquent glioblastoma confers an added survival benefit compared to GTR alone. For patients with non-eloquent glioblastoma, a supramaximal resection by means of an anatomic lobectomy should be considered as a primary surgical treatment in select patients if feasible.

Original languageEnglish (US)
Pages (from-to)501-508
Number of pages8
JournalJournal of neuro-oncology
Issue number3
StatePublished - Jul 1 2020


  • Brain tumor
  • Glioma
  • Gross total resection
  • Lobectomy
  • Outcomes

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection'. Together they form a unique fingerprint.

Cite this